



# **Advisory Commission on Childhood Vaccines (ACCV) update**

**(October 2023 – February 2024)**

**Jay E. Slater, MD**  
**Office of Vaccines Research and Review**  
**Center for Biologics Evaluation and Research**  
**U.S. Food and Drug Administration**  
**7-8 March 2024**

# Novavax COVID-19 Vaccine

**3 October:** amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. The updated vaccine addresses circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death.

# Penbraya

**20 October**: approved Penbraya for the prevention of invasive disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

## Ixchiq

**9 November:** approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus. The chikungunya virus is primarily transmitted to people through the bite of an infected mosquito. Chikungunya is an emerging global health threat with at least 5 million cases of chikungunya virus infection reported during the past 15 years. The highest risk of infection is in tropical and subtropical regions of Africa, Southeast Asia, and parts of the Americas where chikungunya virus-carrying mosquitos are endemic. However, chikungunya virus has spread to new geographical areas causing a rise in global prevalence of the disease.



# Vaccines and Related Biological Products Advisory Committee

**5 October**: met in open session to discuss the Strain Selection for the Influenza Virus Vaccines for the 2024 Southern Hemisphere Influenza Season.

## FDA COVID-19 Website

- FDA has a website dedicated to its COVID-19 activities, including FDA's pandemic response activities pertaining to vaccines, testing, therapeutics, and devices. The website is frequently updated and is a resource for the public, including healthcare providers and industry.  
<https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19>

# Questions?



The opinions expressed herein – *especially in response to questions* – are an informal communication and represent my best judgment. These comments/responses do not bind or obligate FDA.